文献速递皮肤肿瘤

1990至2019年欧盟15+国家皮肤黑色素瘤死亡与发病趋势

Trends in cutaneous melanoma mortality and incidence in European Union 15+ countries between 1990 and 2019.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2025-01-08

基于全球疾病负担数据库,对19个高收入国家1990–2019年皮肤黑色素瘤年龄标化死亡率、发病率、死亡发病比和伤残调整生命年进行横断面分析。多数国家男性死亡率上升,希腊增幅最大(+87%);发病率在所有国家上升但2015年后趋平;近期多数国家死亡率下降,伤残调整生命年基本不变。

要点

  • 多数欧盟15+国家男性皮肤黑色素瘤年龄标化死亡率上升,希腊增幅最大(+87%)。
  • 所有国家发病率上升,但2015年后出现平台期证据。
  • 近期除英国外多数国家死亡率显著下降,伤残调整生命年基本不变。

核心结论

  • 过去30年多数欧盟15+国家皮肤黑色素瘤死亡率和发病率上升,但近年死亡率有下降证据,伤残调整生命年基本不变。

研究设计与样本

  • 基于全球疾病负担数据库1990–2019年的 population-based 横断面研究,纳入19个高收入国家(含英国、美国、澳大利亚及部分欧盟国家)。

主要发现

  • 几乎所有国家男性年龄标化死亡率上升,希腊增幅最大(+87%);女性国家间异质性更大。
  • 所有国家男性死亡率均高于女性。
  • 所有国家发病率上升,2015年后出现平台期证据。
  • 所有国家死亡发病比显著下降,但作者指出其不能作为生存率的替代指标。
  • 伤残调整生命年总体基本不变。

关键数值与推荐

  • 最近一次Joinpoint分析显示,除英国外所有国家死亡率显著下降;英国男性2007–2019年上升0.5%,女性2002–2019年上升0.1%。

临床怎么用

  • 应继续监测皮肤黑色素瘤死亡率与发病率趋势,并加强初级预防而非仅关注昂贵创新疗法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cutaneous melanoma (CM) is the leading cause of skin cancer mortality with associated high healthcare costs. Up-to-date reporting of epidemiological trends for CM is required to project future trends, assess the burden of disease and aid evaluation of new diagnostic, therapeutic and preventative strategies. OBJECTIVES: To describe the trends in CM mortality, incidence, mortality-to-incidence indices (MIIs) and disability-adjusted life years (DALYs) over the last three decades. METHODS: A population-based cross-sectional study of the Global Burden of Disease (GBD) database between 1990 and 2019 was performed. Nineteen high-income countries with similar health expenditure and classified as having high-quality mortality data including the United Kingdom, the United States, Australia and selected European Union countries were included. Annual age-standardized incidence rates (ASIRs), age-standardized death rates (ASDRs) and DALYs for each country were extracted. Mortality-to-incidence indexes were calculated by dividing the ASDR by the ASIR. Trends were described using Joinpoint regression analysis. RESULTS: Almost all countries demonstrated increasing ASDR in males over the observation period with greatest percentage increase in Greece (+87%), and there was greater heterogeneity between countries in females. CM mortality was greater for males than females in all countries. Most recent Joinpoint analysis shows significantly decreasing mortality in all countries except the United Kingdom (+0.5% males between 2007 and 2019, +0.1% females between 2002 and 2019). Incidence rates increased in all countries, with evidence of plateau from 2015 onwards. While MIIs cannot be used as a proxy for survival, statistically significant decreases in MII were observed in all countries. Overall, DALYs remained static. CONCLUSIONS: Over the past 30 years, CM mortality and incidence has increased in most EU15+ countries. There is evidence that in recent years, CM mortality is decreasing. The burden of disease as assessed using DALYs has remained mostly unchanged. Future work should not solely focus on expensive innovative therapies, but also on optimizing primary prevention.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Wang XM, Borsky K, Proctor DW, et al. Trends in cutaneous melanoma mortality and incidence in European Union 15+ countries between 1990 and 2019. J Eur Acad Dermatol Venereol. 2025. PMID: 39780527. doi:10.1111/jdv.20524

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。